Carcinoma of the uterine cervix in Czech Republic and possibilities of its prevence

Download PDF Česká verzia

Authors: Iva Kinkorová Luňáčková ¹; Ondřej Májek ²
Authors place of work: Bioptická laboratoř s. r. o., Plzeň ¹; Institut biostatistiky a analýz, LF MU, Brno ²
Published in the journal: Čes.-slov. Patol., 63, 2018, No. 4, p. 164-168
Category: Přehledový článek

Summary

Carcinoma of the uterine cervix belongs to significant malignancy in the Czech Republic. The goal of organized national cervical cancer screening program is to decrease incidence and mortality of this disease. Discovery of casual relationship between human papillomavirus (HPV) and cervical cancer together with modern examinations methods pushed forward possibilities of primary and secondary prevention worldwide. In the article, there are mentioned basic statistical data of cervical cancer screening in the Czech Republic (the annual coverage of the target population, incidence, prevalence, mortality etc.), types of different screening strategies, evaluation of gynecologic cytology according to the Bethesda system, HPV vaccination and more information related to this topic.

Keywords:

cervix – carcinoma – screening – HPV – vaccination – cytology – Bethesda system

Zdroje

Ngo O, Májek O, Krejčí D, Mužík J, Gregor J, Dušek L. Epidemiologie zhoubného nádoru děložního hrdla v České republice. Gyn Por 2017; 1(5): 270-275.
de Villiers EM, Faugnet C, Broker TR, Bernards HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324(1): 17-27.
Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: role of E6 and E7 proteins. Cancer Sci 2007; 98(10): 1505-1511.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2(5): 342-350.
Powell SE, Hariri S, Steinan M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31(1): 109-113.
Fait T. Trendy v očkování proti HPV v České republice. Gyn Por 2017; 1(5): 278-280.
Mariani L, Preti M, Cristoforoni P, Stigliano CM. Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynaecol Obstet 2017; 136(3): 258-265.
Harper DM, De Mars LR. HPV vaccines-A review of the first decade. Gynecol Oncol 2017; 146(1): 196-204.
Cooper CP, Saraiya M. Primary HPV testing recommendations of US providers, 2015. Prev Med 2017; 105: 372-377.
Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study, Design, methods and characteristics of trial participants. Acta Cytol 2000; 44(5): 726-742.
Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, Ridder R. Triaging HPV-positive woman with p16/ki-67 dual-stained cytology: Results from a sub-study nested into the Athena trial. Gynecol Oncol 2017; 144(1): 51-56.
Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes, ed. 3. New York, Springer 2015.
Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285(11): 1500-1555.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. Tumours of the Uterine Cervix: WHO Classification of the Tumours of Female Reproductive Organ ed. 4. Lyon, IARC Press 2014.
Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32(1): 76-115.
Zhou H, Schwartz MR, Coffey D, Smith D, Mody DR, Ge Y. Should LSIL-H be a distinct cytology category? A study on the frequency and distribution of 40 human papillomaviruses genotypes in 808 women. Cancer Cytopathol 2012; 120(6): 373-379.
Pluta M. Konsensus pro řešení abnormálních nálezů ve screeningu cervikálních karcinomů. Gyn Prom 2009; 9(2): 51-58.
Robová H. Konsensus pro management suspektních a pozitivních cytologických nálezů v graviditě. Gyn Prom 2009; 9(2): 59-61.